Diabetes Board decisions

The Board granted effective dates of September 25, 2009, for right knee bony joint enlargement and instability, and September 3, 2014, for other conditions including Graves' disease, avitaminosis, left knee bony joint enlargement, left knee instability, arthritis, diabetes mellitus, type II, hypertension, and depressive disorder.

The Board granted service connection for bilateral hearing loss, tinnitus, and diabetes mellitus, type II. The claims for right hand tremors and a thoracolumbar spine disorder were remanded.

The Board granted service connection for obstructive sleep apnea, diabetes mellitus, type II, and bilateral Charcot feet as secondary to the Veteran's service-connected disabilities.

The Board denied service connection for diabetes mellitus type II, hypertension, and hypothyroidism as the evidence did not support a finding of in-service exposure to herbicide agents or that the disorders were otherwise related to military service.

The Board granted service connection for ischemic heart disease, for accrued benefits purposes, but denied the claim for accrued benefits based on the Veteran's non-service-connected diabetes mellitus type II.

The Board denied an initial evaluation in excess of 30 percent for unspecified depressive disorder with unspecified insomnia disorder, and remanded the issues of entitlement to an initial evaluation in excess of 20 percent for diabetes mellitus type II and an initial compensable evaluation for hypertension.

The Board denied service connection for diabetes mellitus type II, bilateral hearing loss, tinnitus, an eye disability, hypertension, a left knee disability, a right knee disability, and a sinus disability as there was no evidence of a current disability or that any of the conditions were related to the Veteran's active duty service.

The Board granted service connection for hypertension, diabetes mellitus type II (DM II), and coronary artery disease (CAD) due to presumed exposure to herbicide agents during the Veteran's service.

The appeal was dismissed due to the Veteran's passing in November 2024.

The appeal was denied for various issues, including service connection and increased disability ratings.

The Board granted service connection for hypertension, diabetes, and gout, finding that these conditions are caused or aggravated by the Veteran's service-connected sleep apnea.

The Board dismissed the claim for service connection for diabetes mellitus, type II and denied a rating in excess of 70 percent for a mood disorder due to a general medical condition.

The Board denied service connection for a heart disorder, diabetes mellitus, and sleep apnea as the evidence did not support a diagnosis of these conditions during or near to the period on appeal.

The Board granted service connection for thyroid cancer, hypothyroidism to include Hashimoto's disease, and diabetes mellitus type II based on the persuasive evidence of record.

The Board granted service connection for an acquired psychiatric disorder and obstructive sleep apnea, but denied earlier effective dates and higher ratings for hearing loss and tinnitus.

The Board granted service connection for cervical strain, cervicogenic headaches, right wrist sprain, left elbow disability, right knee degenerative arthritis and right knee strain, and left knee strain. However, it denied service connection for diabetes mellitus, type I, gastroesophageal reflux disease (GERD), hypertension, and remanded claims for chronic fatigue syndrome, right forearm carpal tunnel syndrome, left forearm CTS, a right elbow disability, and a left wrist disability.

The Board granted an effective date of September 3, 2020, for service connection for diabetes mellitus based on the Veteran's timely filed Supplemental Claim Application.

The appeal was dismissed due to the Veteran's death before a final decision could be made.

The motion for reversal or revision of the June 2020 Board decision that denied service connection for diabetes mellitus was denied.

The Board denied service connection for diabetes mellitus, type 2 and denied an initial compensable evaluation for prostate cancer residuals prior to April 3, 2023. However, the Board granted a 10 percent evaluation from April 3, 2023.